Small-molecule inhibitors of cyclophilin D as potential therapeutics in mitochondria-related diseases

Area of Science:

• Biochemistry
• Pharmacology
• Mitochondrial Biology

Background:

• Cyclophilin D (CypD) regulates mitochondrial permeability transition pore (mPTP) opening.
• mPTP dysfunction is implicated in ischemia-reperfusion injury and neurodegeneration.
• CypD inhibition is a potential therapeutic strategy for these diseases.

Purpose of the Study:

• To review current knowledge on CypD inhibitors.
• To focus on small-molecule inhibitors, their activity, selectivity, and binding modes.
• To discuss strategies for enhancing CypD inhibitor molecular design.

Main Methods:

• Literature review of existing CypD inhibitors.
• Analysis of in vitro activity data.
• Examination of selectivity profiles and binding site interactions.
• Discussion of structure-activity relationships and drug design principles.

Main Results:

• Numerous CypD inhibitors have been identified.
• Current inhibitors face challenges with toxicity, pharmacokinetics, and selectivity.
• Understanding binding modes is crucial for rational drug design.

Conclusions:

• CypD inhibition remains a promising therapeutic avenue.
• Overcoming toxicity and selectivity issues is critical for clinical translation.
• Improved molecular design is key to developing effective CypD inhibitors.